Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Friday.

Other equities analysts also recently issued research reports about the stock. Chardan Capital reiterated a "buy" rating and set a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. downgraded Seres Therapeutics from a "neutral" rating to an "underweight" rating in a report on Thursday, October 24th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $5.08.

Seres Therapeutics Trading Up 7.4 %

NASDAQ:MCRB traded up $0.06 during mid-day trading on Friday, hitting $0.91. The stock had a trading volume of 1,518,476 shares, compared to its average volume of 1,304,388. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $2.05. The stock has a 50-day simple moving average of $0.82 and a two-hundred day simple moving average of $0.90. The company has a market capitalization of $154.59 million, a PE ratio of -3.94 and a beta of 2.07.

Institutional Investors Weigh In On Seres Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MCRB. FMR LLC boosted its stake in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company's stock worth $21,625,000 after buying an additional 140,096 shares during the period. Geode Capital Management LLC raised its stake in Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company's stock valued at $1,314,000 after acquiring an additional 255,014 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company's stock worth $708,000 after acquiring an additional 222,771 shares during the period. Vontobel Holding Ltd. purchased a new position in shares of Seres Therapeutics in the 3rd quarter valued at approximately $374,000. Finally, State Street Corp increased its holdings in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after purchasing an additional 43,700 shares during the period. Hedge funds and other institutional investors own 59.34% of the company's stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.